Its inactivation, which is crucial in lung cancer oncogenesis and progression, leads to the upregulation of the PI3K/AKT pathway and increased tumor progression, resulting in poor EGFR-TKI sensitivity in NSCLC patients [136,137,138,139]. This evidence concerns the gene EGFR and lung carcinoma.